Association of various lipid parameters with premature coronary artery disease in men

QR Code

Association of various lipid parameters with premature coronary artery disease in men

Aim. To assess the relationship between premature coronary artery disease (CAD) and various lipid parameters.Material and methods. This retrospective longitudinal study included 166 men aged 57±9 years with coronary CAD with onset before age of 55. The control group consisted of 62 men (60±8 years o...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. V. Tyurina, O. I. Afanas’eva, E. A. Klesareva, N. A. Tmoyan, O. A. Razova, M. V. Ezhov, S. N. Pokrovsky
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2022-07-01
Series:	Российский кардиологический журнал
Subjects:	lipoprotein(a) coronary artery disease hyperlipidemia
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/5058
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Prevalence of familial hypercholesterolemia and hyperlipoproteinemia(a) in patients with premature acute coronary syndrome
by: U. V. Chubykina, et al.
Published: (2022-07-01)

Lipoprotein(a) and Blood Monocytes as Factors for Progression of Carotid Atherosclerosis in Patients with Premature Coronary Heart Disease
by: Alexandra V. Tyurina, et al.
Published: (2025-06-01)

Lipoprotein(a) concentration and the blood content of INFγ-producing T-helpers 17 (Th17/1) in males with premature coronary artery disease
by: A. Yu. Filatova, et al.
Published: (2022-07-01)

Role of inflammation, autotaxin and lipoprotein (a) in degenerative aortic valve stenosis in patients with coronary artery disease
by: A. L. Burdeynaya, et al.
Published: (2021-03-01)

Lipoprotein(a), homocysteine and coronary atherosclerosis in young and middle-aged men
by: M. V. Ezhov, et al.
Published: (2008-10-01)

Lipid-lowering therapy: modern possibilities and real clinical practice
by: A. V. Blokhina, et al.
Published: (2022-09-01)

Effectiveness of lipid-lowering therapy in outpatients with coronary artery disease living in a large industrial center of Eastern Siberia
by: N. G. Gogolashvili, et al.
Published: (2022-01-01)

A Molecular and Biochemical Study for Cholesteryl Ester Transfer Protein (CETP) Taq1B in Iraqi Patients with Hyperlipidemia
by: Alkhafajy et al.
Published: (2019-09-01)

EFFECT OF SIMVASTATIN ON MARKERS OF CARDIOVASCULAR RISK
by: N. V. Perova, et al.
Published: (2016-01-01)

Rosuvastatin safety and efficacy in coronary heart disease patients
by: I. V. Sergienko, et al.
Published: (2006-10-01)

Choosing lipid lowering statin in risk strategy of cardiovascular event prevention
by: A. Ya. Yvleva, et al.
Published: (2007-02-01)

The heterogeneity of lipoproteins and their role in the development of cardiovascular diseases
by: E. A. Utkina, et al.
Published: (2019-06-01)

INFLUENCE OF NICOTINIC ACID ON SUBFRACTIONAL SPECTRUM OF LOW, INTERMEDIATE AND HIGH DENSITY LIPOPROTEINS IN PATIENTS WITH HYPERLIPOPROTEINEMIA(а)
by: E. A. Utkina, et al.
Published: (2017-06-01)

ANTISENSE OLIGONUCLEOTIDES AND THERAPEUTICAL MONOCLONAL ANTIBODIES AS A BASEMENT FOR NOVEL BIOLOGICAL LIPIDLOWERING DRUGS
by: O. I. Afanasieva, et al.
Published: (2018-09-01)

Nature behavioral responses, lipid profile and state of cardiovascular system in lead intoxication modelling on the background of hyperlipidemia in albino rats
by: N. L. Yakimova, et al.
Published: (2016-09-01)

Lipid Clinic is an Efficacious Model of Preventive Medicine
by: A. V. Blokhina, et al.
Published: (2021-03-01)

Review and analysis of 2023 Clinical Guidelines for Lipid Metabolism Disorders
by: I. V. Sergienko, et al.
Published: (2023-12-01)

COMPLEX ASSESSMENT OF EFFICACY OF STATINS PRESCRIBED AT MOST BY CLINICIANS
by: A. S. Sivkov, et al.
Published: (2018-06-01)

ESCADRA: a randomised study. Part I: lipid-lowering effectiveness, safety and tolerability of ezetimibe, initial doses of original statins, and the combination of ezetimibe with initial doses of statins in patients with coronary heart disease and hyperlipidemia
by: M. Yu. Zubareva, et al.
Published: (2010-12-01)

Features of lipid metabolism disturbances in patients with rheumatoid arthritis
by: A E Sizikov, et al.
Published: (2009-04-01)

Hyperlipoproteinemia(a) as a dangerous genetically determined violation of lipid metabolism and a risk factor for atherothrombosis and cardiovascular diseases
by: O. I. Afanasieva, et al.
Published: (2019-06-01)

Serum lipids and smoking status in coronary heart disease patients treated with simvastatin
by: L. R. Gazdanova, et al.
Published: (2010-04-01)

Atherogenic hyperadrenoreactivity in men with arterial hypertension
by: S. S. Bunova, et al.
Published: (2009-02-01)

Evaluation of lipid profiles in patients with chronic spontaneous urticaria: A case-control study
by: Abbas Khalili, et al.
Published: (2025-03-01)

NOVEL OPPORTUNITIES TO REACH THE TARGET LEVELS OF LOW DENSITY CHOLESTEROL
by: M. V. Ezhov
Published: (2014-08-01)

Lipoprotein (a) polymorphism as a risk factor of coronary and carotid atherosclerosis and its complications in women
by: O. I. Afanasyeva, et al.
Published: (2010-12-01)

The era of targeted therapy for hyperlipidemia
by: U. V. Chubykina, et al.
Published: (2024-10-01)

Effect of total alkaloids from lotus leaves on body mass and lipid regulation in vivo and in vitro
by: FAN Tingting, et al.
Published: (2013-03-01)

PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center
by: A. V. Blokhina, et al.
Published: (2022-01-01)

Do symptoms arise from hyperlipidemia due to hyperviscosity or through its atherosclerotic consequences? – A case series exploration
by: Amit Chakraborty, et al.
Published: (2025-08-01)

Ezetimibe potential in cardiology practice
by: A. A. Lyakishev, et al.
Published: (1970-01-01)

Number of blood neutrophil granulocytes is associated with diffuse coronary involvement in patients with increased lipoprotein (a)
by: A. Yu. Filatova, et al.
Published: (2023-11-01)

Modification of blood lipoprotein and apolipoprotein levels by physical exercise of various type and intensity in healthy men with normo- and hyperlipidemia
by: M. G. Bubnova, et al.
Published: (2005-04-01)

Clinical-laboratory evaluation of overweight and obese cats seen in routine clinical practice
by: Steffi L. Araujo, et al.
Published: (2025-07-01)

EFFICIENCY AND SAFETY ASSESSMENT OF GENERIC ATORVASTATINE IN PATIENTS WITH HYPERLIPIDEMIA
by: J. E. Semyonova, et al.
Published: (2015-12-01)

SPECIFICS OF SUBFRACTIONAL SPECTRUM OF APOLIPOPROTEIN B RELATED LIPOPROTEINES IN CAROTID OR CORONARY ATHEROSCLEROSIS PATIENTS
by: N. E. Gavrilova, et al.
Published: (2016-10-01)

Role of lipid metabolic disturbances for the mechanisms of immune dysregulation and endothelial dysfunction in early forms of chronic cerebrovascular insufficiency
by: E. V. Davydova, et al.
Published: (2020-01-01)

ANTIATHEROGENIC AND PLEIOTROPIC ACTIVITY OF VARIOUS DOSES OF ATORVASTATIN IN PATIENTS WITH ISCHEMIC STROKE
by: M. G. Bubnova, et al.
Published: (2013-08-01)

2019 ESC/EAS Guidelines for themanagement of dyslipidaemias: lipid modification to reduce cardiovascular risk
by: Francois Mach, et al.
Published: (2020-06-01)

Study the level of lipid oxidation in patients with coronary atherosclerosis
by: Sabah Hussein Khorsheed, et al.
Published: (2023-01-01)